DARK SECRETS: Optn | Rare Historical Photos

Federal Reviewers Found Problems in Nearly 30 Percent of Cases at a Four-State Organ Procurement Group

HHS moved to decertify Network for Hope after federal reviews found concerning features in 103 of 351 organ donation cases examined.

Medical Daily · Aug 11

3 Pharma Stocks to Snatch up During Market Dips

The pharmaceutical industry is undergoing rapid growth and expansion, driven by rising medical needs, favorable regulatory measures, and the implementation of pharma 4.0. Hence, investors could snatch up quality pharma stocks Bristol-Myers Squibb (BMY), Spero Therapeutics (SPRO), and OptiNose (OPTN) for steady returns during market dips. Read more.

StockNews.com · May 3, 2024

Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now

With rising medicine demand and drug shortages in the U.S., pharmaceutical stocks under $20 present lucrative opportunities for investors, promising substantial returns in a ripe market. So, I think fundamentally solid pharma stocks ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), and OptiNose (OPTN), which are currently trading under $20, could be…

StockNews.com · May 2, 2024

Biden administration plans overhaul of organ transplant system

WASHINGTON — The Health Resources and Services Administration on Wednesday unveiled plans to break up the private nonprofit overseeing the nation’s organ transplantation system, and called on Congress to help.

Tribune News Service · Mar 22, 2023

Biden administration plans overhaul of organ transplant system - Roll Call

More than 100,000 Americans are currently waiting for an organ and an estimated 17 people die each day on the waiting list.

Roll Call · Mar 22, 2023

Looking Into OptiNose's Return On Capital Employed

Benzinga Pro data, OptiNose (NASDAQ:OPTN) reported Q1 sales of $14.76 million. Earnings fell to a loss of $25.33 million, resulting in a 62.14% decrease from last quarter.

Benzinga · Jun 16, 2022

Optinose Stock Moves Higher On Positive Second Chronic Sinusitis Phase 3 Trial

Optinose Inc (NASDAQ:OPTN) announced the statistically significant benefits of XHANCE in the ReOpen2 trial for the symptoms co-primary endpoint and the CT scan co-primary endpoint.  Significant improvement was seen in patients with chronic sinusitis who did not have nasal polyps treated with both doses of XHANCE (fluticasone propionate) nasal spray compared to a…

Benzinga · Jun 13, 2022

OptiNose: Q1 Earnings Insights

  OptiNose (NASDAQ:OPTN) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 12, 2022

OptiNose Earnings Preview

OptiNose (NASDAQ:OPTN) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that OptiNose will report an earnings per share (EPS) of $-0.27.

Benzinga · May 11, 2022

OptiNose's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q4, OptiNose's (NASDAQ:OPTN) reported sales totaled $22.51 million. Despite a 8.72% increase in earnings, the company posted a loss of $15.62 million.

Benzinga · Mar 10, 2022